Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that following its acquisition of Cytocell in March, it will directly sell Cytocell products to the North American market.

New and existing Cytocell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure, which will be further enhanced through additional appointments in the coming months.

OGT’s acquisition of Cytocell saw the addition of a portfolio of Fluorescence In Situ Hybridisation (FISH) probes to its CytoSure™ cytogenetics array and Genefficiency™ next generation sequencing products and services, expanding the company’s genomic medicine offering.

Dr Martin Lawrie, Managing Director of Cytocell said: “The global cytogenetics market is predicted to grow by 23% a year to $2 billion by 2019, and with North America accounting for approximately 50% of the market, OGT is now well placed to better serve this increasing customer base with a wider range of products. The integration of Cytocell into the OGT group has proceeded extremely smoothly with very positive, immediate benefits for our customers. OGT’s excellent and expanding sales team will provide our customers with the best possible sales and support experience moving forward.”

In June, scientists can find out about OGT’s extended genomic medicine portfolio at:

• International Collaboration for Clinical Genomics Conference, 11-12 June, Bethesda, MD, USA
• Association of Genetic Technologists 39th Annual Meeting, 12-14 June, Louisville, KY, USA

more about oxford gene technology

more news from oxford gene technology